Biofocus
BioFocus DPI is a multinational company that aim to expand their partners' drug pipeline by accelerating the gene-to-candidate drug discovery process. They offer a biologically-focused discovery platform utilising target discovery in human prmary cells and chemogenomically-designed compound libraries.
Birkbeck
CRT and Birkbeck have entered an agreement that enables CRT employees to be based within the college’s School of Crystallography, part of the Birkbeck/UCL Institute of Structural Molecular Biology. They will study the structures of drug-protein complexes to aid CRT’s anticancer drug discovery projects.
Cancer Therapeutics CRC (CTx)
CTx is a dedicated cancer drug discovery and development company underpined by AUD148M in public / private partnership funds to drive the best small-molecule cancer research to cancer drug candidates over the next seven years.
They work closely with leading Australian researchers and institutes to discover, protect and develop small molecule discoveries into pre-clinical drug candidates with commercial potential.
Their specific focus is small molecule cancer drugs or enabling therapeutics for single or co-therapy regimes - the next generation of global cancer therapies. CTx is well placed to do this, with internationally-respected expertise in molecular and cellular biology, drug discovery, pharmacology, structural biology and medicinal chemistry and with a global commercialisation partner (CRT) in cancer therapeutics to take the successful drug candidates forward through clinical development and to the market.
|
